Methods and formulation for improving oral availability of cpt-11 while reducing cpt-11 induced gastrointestinal toxicity in cancer therapy
AssigneeJohnpro Biotech Inc.
InventorsPei-Ru LIAO, Kwan-Hwa CHI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and formulation for enhancing oral availability of CPT-11 during cancer therapy while at the same time, reducing its gastrointestinal (GI) toxicity, thus the methods and formulations as disclosed herein may augment the efficacy of cancer therapy.
Claims21
A method of reducing CPT-11 induced gastrointestinal (GI) toxicity in a subject underwent a CPT-11 treatment, comprising,
- administering 1-50 mg/Kg of silychristin to the subject so as to ameliorate or alleviate symptoms of CPT-11 induced GI toxicity.
A method for improving oral availability of CPT-11 while reducing its gastrointestinal (GI) toxicity in a subject underwent a CPT-11 treatment, comprising administering to the subject in sequence, one dose of ursodeoxycholic acid (UDCA) that is about 0.1-10 mg/Kg;
- and
- at least one dose of silymarin, in which each dose of silymarin is about 1-50 mg/Kg;
- wherein each doses of silymarin is administered prior to, concurrently with, or after the CPT-11 treatment.
21-57. (canceled)
Dependencies are inferred from the claim text.